European biotechnology leadership and innovation are under pressure.
For Europe to remain a hub for innovation and production, we need accelerated regulatory processes and consistent support frameworks – factors currently driving business growth across the Atlantic.
This was the key message from our co-founder and CEO, Thomas Schmidt, in the news this morning on TV 2 Denmark. As a business leader in the field of biosolutions, Thomas was interviewed to share his insights and recommendations.
At 21st.BIO, we offer world-leading production technology to make proteins for nutrition widely and readily available. Yet, our customers are increasingly incentivized to establish production in the US rather than Europe due to faster regulatory approvals, relatively more attractive operating costs and more stable support schemes.
We hope that both the EU and national governments in Europe will make this a top priority, especially during the upcoming Danish EU Presidency.
